Showing results (81-90 of 120) with videos related to
Sort By:
Pageof 12
Antimicrobial Agents and Chemotherapy|February 15, 2018
Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C VirusDarius Babusis, Michael P Curry, Brian Kirby, et al.Rheumatology Advances in Practice|August 22, 2019
Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic reviewChristopher J Edwards, Patrick Kiely, Subhashini Arthanari, et al.Rheumatology International|March 23, 2018
Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritisBruno Fautrel, Rieke Alten, Bruce Kirkham, et al.JAMA Dermatology|July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisZenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 27, 2015
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIVMaribel Rodriguez-Torres, Anuj Gaggar, Gong Shen, et al.Arthritis Research & Therapy|July 7, 2017
Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritisAgnes Szentpetery, Eric Heffernan, Martina Gogarty, et al.Oncogene|May 5, 2005
A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer modelNoreen Majeed, Marie-José Blouin, Paula J Kaplan-Lefko, et al.Experimental Dermatology|December 17, 2013
Notch-1 mediates endothelial cell activation and invasion in psoriasisPeadar Rooney, Mary Connolly, Wei Gao, et al.BMC Urology|April 17, 2015
Effects of tadalafil treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase IV studyHitendra R Patel, Dapo Ilo, Nimish Shah, et al.Dermatology and Therapy|November 22, 2025
Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare ProfessionalsRaymond Matthews, April W Armstrong, Matthias Augustin, et al.Pageof 12